We Offer Worldwide Shipping
Login Wishlist

6,7-Dihydroxycoumarin-4-Acetic Acid


  • Brand : BIOFRON

  • Catalogue Number : BN-O1459

  • Specification : 98%(HPLC)

  • CAS number : 88404-14-2

  • Formula : C11H8O6

  • Molecular Weight : 236.18

  • PUBCHEM ID : 5393159

  • Volume : 20mg

Available on backorder

Checkout Bulk Order?

Catalogue Number


Analysis Method





Molecular Weight



Botanical Source

Structure Type





2-(6,7-dihydroxy-2-oxochromen-4-yl)acetic acid


2-(6,7-dihydroxy-2-oxochromen-4-yl)acetic acid



Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

Boiling Point

Melting Point



InChl Key


WGK Germany


HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:88404-14-2) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.




Purpose of the Study:
To examine whether Veteran status influences (a) women’s survival to age 80 years without disease and disability and (b) indicators of successful, effective, and optimal aging at ages 80 years and older.

Design and Methods:
The Women’s Health Initiative (WHI) enrolled 161,808 postmenopausal women aged 50-79 years from 1993 to 1998. We compared successful aging indicators collected in 2011-2012 via mailed questionnaire among 33,565 women (921 Veterans) who reached the age of 80 years and older, according to Veteran status. A second analysis focused on women with intact mobility at baseline who could have reached age 80 years by December 2013. Multinominal logistic models examined Veteran status in relation to survival to age 80 years without major disease or mobility disability versus having prevalent or incident disease, having mobility disability, or dying prior to age 80 years.

Women Veterans aged 80 years and older reported significantly lower perceived health, physical function, life satisfaction, social support, quality of life, and purpose in life scale scores compared with non-Veterans. The largest difference was in physical function scores (53.0 for Veterans vs 59.5 for non-Veterans; p < .001). Women Veterans were significantly more likely to die prior to age 80 years than non-Veteran WHI participants (multivariate adjusted odds ratio = 1.20; 95% confidence interval, 1.04-1.38). In both Veteran and non-Veteran women, healthy survival was associated with not smoking, higher physical activity, healthy body weight, and fewer depressive symptoms. Implications: Intervening upon smoking, low physical activity, obesity, and depressive symptoms has potential to improve chances for healthy survival in older women including Veterans.


Healthy aging, disability, Quality of life, Women Veterans


Aging Well Among Women Veterans Compared With Non-Veterans in the Women’s Health Initiative


Andrea Z. LaCroix, PhD,*,1 Eileen Rillamas-Sun, PhD, MPH,2 Nancy F. Woods, PhD, RN,3 Julie Weitlauf, PhD,4,5 Oleg Zaslavsky, PhD,6 Regina Shih, PhD,7 Michael J. LaMonte, PhD, MPH,8 Chloe Bird, PhD, MA,9 Elizabeth M. Yano, PhD, MSPH,10,11 Meryl LeBoff, MD,12 Donna Washington, MD, MPH,10 and Gayle Reiber, PhD, MPH13,14

Publish date

2016 Feb;




Background: The distinction of genera in Cranaidae (as in many other Gonyleptoidea) is traditionally made on the basis of a combination of armature of scutal areas, tarsomere counts, and some secondary sexual structures (which may vary among males). This historically led to the creation of non-natural groups of species as meaningless genera. Here some nominal genera of Cranaidae are addressed, and this paucity of diagnostic characters is alleviated with more detailed diagnoses and descriptions.

Results: The poorly known genus Ventrifurca Roewer, 1913, hitherto monotypic, is revisited. The genera Microcranaus Roewer, 1913 (with three species), Cayabeus Roewer, 1932 (monotypic), and Angistrius (monotypic) are here proposed as junior subjective synonyms of Ventrifurca. Both type species of Microcranaus and Cayabeus are considered junior subjective synonyms of Ventrifurca albipustulata; thus, Cayabeus perlatus Roewer, 1932 and Microcranaus pustulatus Roewer, 1913 = Ventrifurca albipustulata Roewer, 1913. Ventrifurca abnormis comb. nov. is proposed for Angistrius abnormis Roewer, 1932. Rhopalocranaus dybasi Goodnight & Goodnight, 1947, currently Neocranaus dybasi, is transferred to Ventrifurca, and the new combination Ventrifurca dybasi comb. nov. is herein proposed for it. Ventrifurca albipustulata is redescribed, and for the first time, the male genitalia is described and illustrated, and SEM pictures are offered. The new species Ventrifurca caffeinica sp. nov. is described from Quindio department, Colombia. A new diagnosis to Ventrifurca is proposed. The relationships of Ventrifurca are discussed. The remaining two species of Microcranaus are transferred to the family Manaosbiidae: (1) Microcranaus columbianus newly combined as Rhopalocranaus columbianus (Roewer, 1963) and (2) Microcranaus gracilis newly combined as Camelianus gracilis(Roewer, 1913). New diagnoses are given for both species.

Conclusions: A non-monotypic genus of Andean Cranaidae is defined, associated with a well-defined geographic region, and unloaded of extraneous species which belong to another family. Recognition of variation in heteromorphic males reveals past errors of assignment when only limited samples were available for study


The poorly known genus Ventrifurca Roewer, 1913 revisited (Opiliones: Cranaidae)


Osvaldo Villarreal M,1,* Adriano B Kury,1 and Ricardo Pinto-da-Rocha2

Publish date





Prospective, population-based study of an 8-year follow up.

To determine the direct cost of diabetic retinopathy [DR], evaluating our screening programme and the cost of treating DR, focusing on diabetic macular oedema [DMO] after anti-vascular endothelial growth factor [anti-VEGF] treatment.

A total of 15,396 diabetes mellitus [DM] patients were studied. We determined the cost-effectiveness of our screening programme against an annual programme by applying the Markov simulation model. We also compared the cost-effectiveness of anti-VEGF treatment to laser treatment for screened patients with DMO.

The cost of our 2.5-year screening programme was as follows: per patient with any-DR, €482.85 ± 35.14; per sight-threatening diabetic retinopathy [STDR] patient, €1528.26 ± 114.94; and €1826.98 ± 108.26 per DMO patient. Comparatively, an annual screening programme would result in increases as follows: 0.77 in QALY per patient with any-DR and 0.6 and 0.44 per patient with STDR or DMO, respectively, with an incremental cost-effective ratio [ICER] of €1096.88 for any-DR, €4571.2 for STDR and €7443.28 per DMO patient. Regarding diagnosis and treatment, the mean annual total cost per patient with DMO was €777.09 ± 49.45 for the laser treated group and €7153.62 ± 212.15 for the anti-VEGF group, with a QALY gain of 0.21, the yearly mean cost was €7153.62 ± 212.15 per patient, and the ICER was €30,361.

Screening for diabetic retinopathy every 2.5 years is cost-effective, but should be adjusted to a patient’s personal risk factors. Treatment with anti-VEGF for DMO has increased costs, but the cost-utility increases to 0.21 QALY per patient.


Diabetic retinopathy, Diabetic macular oedema, Telemedicine, Cost of diabetic macular oedema, Cost of diabetic retinopathy screening


Cost of diabetic retinopathy and macular oedema in a population, an eight year follow up


Pedro Romero-Aroca,corresponding author1,6 Sofia de la Riva-Fernandez,1 Aida Valls-Mateu,2 Ramon Sagarra-Alamo,3,4,5 Antonio Moreno-Ribas,2 Nuria Soler,1 and Domenec Puig2

Publish date


Description :

Empty ...